RECRUITING

SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

SCOPE is an observational, prospective study of HIV-1 infected volunteers designed to provide a specimen bank of samples with carefully characterized clinical data. SCOPE specimens will be used to examine multiple questions involving virologic, immunologic, and host factors involved in HIV-1 infection, progression, non-progression, response to treatment, control of HIV-1 virus, and evolution of drug resistance.

Official Title

SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era

Quick Facts

Study Start:2000-03
Study Completion:2033-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT00187512

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Documented HIV viral load less than 2000 copies/ml WITHOUT taking antiretroviral therapy
  2. 2. Undetectable HIV viral load with CD4 T-cells consistently less than 350 for the last 12 months while taking a stable antiretroviral regimen.
  3. 3. Antiretroviral naive and planning to start an antiretroviral regimen - any CD4 or HIV viral load acceptable.
  4. 4. Long-term Non Progressors: HIV-positive at least 10 years, no antiretroviral therapy for the past 10 years or more, any viral load acceptable, CD4-T cell count always above 500.
  1. 1. Active opportunistic infection or systemic treatment for opportunistic infection within the last 4 months (oral candidiasis acceptable)
  2. 2. Active treatment for cancer
  3. 3. Active treatment for hepatitis C requiring interferon based therapy
  4. 4. Immunosuppressive therapy taken within the last 4 months

Contacts and Locations

Study Contact

Rebecca Hoh, M.S., R.D.
CONTACT
415-476-4082
Rebecca.Hoh@ucsf.edu
Montha Pao
CONTACT
415-476-4082
Montha.Pao@ucsf.edu

Principal Investigator

Steven G. Deeks, M.D.
PRINCIPAL_INVESTIGATOR
University of California, San Francisco

Study Locations (Sites)

San Francisco General Hospital
San Francisco, California, 94110
United States

Collaborators and Investigators

Sponsor: University of California, San Francisco

  • Steven G. Deeks, M.D., PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2000-03
Study Completion Date2033-12

Study Record Updates

Study Start Date2000-03
Study Completion Date2033-12

Terms related to this study

Keywords Provided by Researchers

  • HIV
  • Antiretroviral Agents
  • Drug Resistance, Multiple
  • Long Term Non Progression
  • Long Term Non Progressor
  • Elite Suppression
  • Elite Suppressor
  • Natural History
  • Observational

Additional Relevant MeSH Terms

  • HIV Infections